Eris Lifesciences Ipo
- All
- News
-
Eris Lifesciences Shares Rise 4% On Stock Market Debut
Shareholders in Eris Lifesciences including private equity firm ChrysCapital sold a total 28.8 million shares in a price range of Rs 600-603 rupees each.
-
Eris Lifesciences To Make Stock Market Debut On Thursday
The book running lead managers to the offer were Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).
-
Eris Lifesciences Up To $270 Million IPO Oversubscribed
Anchor investors including Abu Dhabi Investment Authority bought 12.9 million shares as part of the IPO at Rs 603 apiece.
-
Eris Lifesciences IPO Subscribed 75% On Day 2
The IPO, to raise Rs 1,741 crore, received bids for1,20,33,096 shares against the total issue size of 1,59,48,750shares, data available with the NSE showed.
-
Eris Lifesciences IPO Opens: Should You Invest?
Eris Lifesciences IPO is unlikely to be affected by the weak sentiment towards pharma sector as it is purely a domestic focused company with focus on lifestyle related diseases and without any product being under price control, say analysts.
-
Eris Lifesciences Shares Rise 4% On Stock Market Debut
Shareholders in Eris Lifesciences including private equity firm ChrysCapital sold a total 28.8 million shares in a price range of Rs 600-603 rupees each.
-
Eris Lifesciences To Make Stock Market Debut On Thursday
The book running lead managers to the offer were Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).
-
Eris Lifesciences Up To $270 Million IPO Oversubscribed
Anchor investors including Abu Dhabi Investment Authority bought 12.9 million shares as part of the IPO at Rs 603 apiece.
-
Eris Lifesciences IPO Subscribed 75% On Day 2
The IPO, to raise Rs 1,741 crore, received bids for1,20,33,096 shares against the total issue size of 1,59,48,750shares, data available with the NSE showed.
-
Eris Lifesciences IPO Opens: Should You Invest?
Eris Lifesciences IPO is unlikely to be affected by the weak sentiment towards pharma sector as it is purely a domestic focused company with focus on lifestyle related diseases and without any product being under price control, say analysts.
